Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

SURF, Neurodevelopment, Growth Study in SGA Infants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04360967
Recruitment Status : Withdrawn (Sponsor decision stopped in June 2017)
First Posted : April 24, 2020
Last Update Posted : April 24, 2020
Sponsor:
Information provided by (Responsible Party):
Nestlé

Brief Summary:
The purpose of this study is to determine whether term SGA infants who are fed a nutrient-enriched pre-term formula will have a higher cognitive score, a more appropriate length-for-age Z-score (leading to a lower prevalence of Stunting) but higher blood pressure at 2 years of age compared to term SGA infants who are fed on a regular starter formula.

Condition or disease Intervention/treatment Phase
Infant, Small for Gestational Age Other: Standard Formula Other: Nutrient-enriched Formula Not Applicable

Detailed Description:

This is multi-sites, interventional, double-blinded, randomized, 2-arm parallel-group clinical trial. Two HM fed groups will be included as comparator group.

The primary objectives are:

  1. To evaluate neurodevelopment at 2 years of age in term small-for-gestational age (SGA) infants fed standard formula or nutrient-enriched formula from 1 to 6 months of age and compare to each human milk (HM)-fed group.
  2. To evaluate length-for-age Z-score at 2 years of age in term SGA infants fed standard formula or nutrient-enriched formula from 1 to 6 months of age and compare to each HM-fed group.
  3. To evaluate systolic blood pressure at 2 years of age in term SGA infants fed standard formula or nutrient-enriched formula from 1 to 6 months of age and compare to each HM-fed group.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Neurodevelopment, Growth, and Metabolic Syndrome Biomarkers in Term Small-for-gestational-age Infants Fed Standard or Nutrient-enriched Formula
Estimated Study Start Date : March 31, 2017
Estimated Primary Completion Date : June 2, 2017
Estimated Study Completion Date : June 2, 2017

Arm Intervention/treatment
Experimental: Randomized Standard Formula-fed
Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
Other: Standard Formula
Standard Formula

Experimental: Randomized Nutrient-enriched formula-fed
Product will be given to the formula-fed groups during the intervention phase of the study (enrollment to age 6 months).
Other: Nutrient-enriched Formula
Nutrient-enriched Formula

No Intervention: Non-randomized HM-fed
Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.
No Intervention: Non-Randomized HM-fed
Infants in HM-fed group will be fed through 6 months of age, along with micronutrient supplementation per routine clinical practice.



Primary Outcome Measures :
  1. Evaluation of neurodevelopment [ Time Frame: at the baseline (2 years of age) ]
    Assessed using Bayley Scales of Infant and Toddler Development® - Third Edition - (To compare with the standard Bayley scores).

  2. Evaluation of length-for-age Z-score [ Time Frame: Evaluated once at 2 years of age ]
    Using the WHO growth chart

  3. Systolic Blood pressure [ Time Frame: at baseline (2 years of age) ]
    Systolic and diastolic blood pressure measurement from 1 to 6 months of age


Secondary Outcome Measures :
  1. Evaluation of insulin sensitivity [ Time Frame: at Baseline ( 2 years of age). ]
    HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) calculated from Basal (Fasting) plasma glucose and insulin concentrations.

  2. Evaluation of insulin sensitivity [ Time Frame: at last visit ( 5 years of age). ]
    HOMA-IR (Homeostatic Model Assessment - Insulin Resistance) calculated from Basal (Fasting) plasma glucose and insulin concentrations.

  3. Neurodevelopment [ Time Frame: At last visit ( 5 years of age) ]
    Assessed using Wechsler Preschool and Primary Scale of Intelligence™ - Fourth Edition (WPPSI-IV) - (to compare the scores against the standard scores).

  4. Safety (Adverse Event reporting) [ Time Frame: From 1 to 6 months of age & 6 months to 5 years of age. ]
    Assessed by Type, incidence, severity, seriousness and relationship to study formulas of AEs (including Infection) among the study subjects.

  5. Growth (Length) [ Time Frame: At 2 years of age ]
    Evaluation of length-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).

  6. Growth (Weight) [ Time Frame: At 2 years of age ]
    Evaluation of weight-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).

  7. Growth (Head circumference) [ Time Frame: At 2 years of age ]
    Evaluation of head circumference-for-age in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).

  8. Growth (Z-Scores) [ Time Frame: At 2 years of age ]
    Evaluation of weight-for-length Z-scores in each formula-fed group by Percentages of study population with length-for-age Z-score less than 2.5th, 5th and 10th Percentile on the WHO reference curve(<2.5th percentile indicating prevalence of stunting).

  9. Evaluation of serum markers of bone metabolism [ Time Frame: At visit 1 (<44 days) ]
    Assessed by Incidence of abnormal serum (Calcium, phosphorus, Alkaline phosphatase).

  10. Evaluation of serum markers of bone metabolism [ Time Frame: At visit 4 (6 months) ]
    Assessed by Incidence of abnormal serum (Calcium, phosphorus, Alkaline phosphatase).

  11. Evaluation of urinary markers of bone metabolism [ Time Frame: At visit 1 (<44 days) ]
    Assessed by Incidence of urine biochemistries (calcium, phosphorous).

  12. Evaluation of urinary markers of bone metabolism [ Time Frame: At visit 4 (6 months) ]
    Assessed by Incidence of urine biochemistries (calcium, phosphorous).

  13. Body fat mass (%) [ Time Frame: evaluated until 5 years of age. ]
    Assessed by Deterium dilution



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   up to 44 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Having obtained his/her parents' (or his/her legally accepted representative's LAR's]) written informed consent and having evidence of a personally signed and dated informed consent document indicating that the infant's parents/LAR have been informed of pertinent aspects of the study.
  2. For infants in formula fed groups only: infants who require formula feeding due to lactation failure after minimum 2 rounds of breastfeeding counselling.
  3. Birth Weight < 10th percentile at term using the 2013 INTERGROWTH-21st Growth Charts for girls and boys.
  4. Full term birth (gestational age ≥ 37 weeks and ≤ 41 weeks + 6 days), with gestational age estimated using fetal anthropometry by ultrasonography in early 1st trimester of pregnancy or calculated using the first day of the last menstrual period + 40 weeks if fetal anthropometry data for term calculation is not available or was collected after the 1st trimester.
  5. Age <45 days at time of enrollment
  6. For infants in the HM-fed AGA comparator group only: born to mothers with pre-pregnancy body mass index (BMI) ≥ 18.5 and <25kg/m2

Exclusion Criteria:

  1. mothers with Type-1 Diabetes
  2. mothers who smoked >10 cigarettes per day during pregnancy.
  3. mothers who used Illicit drugs (e.g. marijuana, cocaine, amphetamines, or heroin) or alcohol (>3 alcoholic beverages per week) during pregnancy
  4. Suspected or documented systemic or congenital infections (e.g Human Immunodeficiency virus, cytomegalovirus)
  5. Genetic or any other type of congenital malformations, metabolic, cardiovascular, gastrointestinal, pancreatic or hepatic diseases or medical conditions that could compromise growth and/or food intake.
  6. Fit to be discharged from neonatal intensive care unit (NICU) in > 5 consecutive days with the exception of infants in the NICU due to jaundice only.
  7. Known or suspected intolerance/ allergy to milk protein or any ingredient in the study formulas
  8. For infants in the HM-fed groups only: infants who are consuming fortified human milk or formula.
  9. Participation in any other interventional clinical trial during the 14 days prior to enrollment.
  10. Infants or infant's family who in the investigator's judgement cannot be expected to comply with the protocol or study procedures.
Layout table for additonal information
Responsible Party: Nestlé
ClinicalTrials.gov Identifier: NCT04360967    
Other Study ID Numbers: 14.11.INF
First Posted: April 24, 2020    Key Record Dates
Last Update Posted: April 24, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Nutrients
Growth Substances
Physiological Effects of Drugs